Activated p53 in the anti-apoptotic milieu of tuberous sclerosis gene mutation induced diseases leads to cell death if thioredoxin reductase is inhibited.

Activated p53 in the anti-apoptotic milieu of tuberous sclerosis gene mutation induced diseases leads to cell death if thioredoxin reductase is inhibited.
复制标题

如果抑制硫氧还蛋白还原酶,则在结核性硬化基因突变的抗凋亡环境中活化的p53会导致细胞死亡。

DOI:
10.1007/s10495-021-01670-4
复制
发表时间:
2021-06
期刊:
Apoptosis : an international journal on programmed cell death
影响因子:
--
通讯作者:
Pongracz JE
Pongracz JE
中科院分区:
其他
文献类型:
--
作者:
Abdelwahab EMM;Bovari-Biri J;Smuk G;Fillinger J;McPhail D;Krymskaya VP;Pongracz JE

文献摘要

参考文献

被引文献

相似文献

结节性硬化症、血管平滑肌脂肪瘤和淋巴管平滑肌瘤病是一组以结节性硬化症基因(TSC 1-2)突变为特征的疾病。 TSC 突变导致 mTOR 通路持续激活,需要适应增加的 ATP 需求。由于治疗选择有限,越来越需要确定新的治疗靶点并了解 mTOR 通路激活与 TSC 突变存在下细胞死亡缺乏之间的相关性。在当前的研究中,我们证明了 p53 控制的和线粒体相关的细胞死亡过程的失调。该研究还表明,用候选药物 Proxison 结合降低浓度的雷帕霉素治疗 TSC 突变细胞可以增加活性氧 (ROS) 的产生,可以改变与 p53 调节相关的 miRNA 表达模式,并可以降低细胞活力。在线版本包含可在 10.1007/s10495-021-01670-4 获取的补充材料。
Tuberous sclerosis, angiomyolipoma and lymphangioleiomyomatosis are a group of diseases characterized by mutation in tuberous sclerosis genes (TSC 1-2). TSC mutation leads to continuous activation of the mTOR pathway that requires adaptation to increased ATP requirement. With limited treatment options, there is an increasing demand to identify novel therapeutic targets and to understand the correlations between mTOR pathway activation and the lack of cell death in the presence of TSC mutation. In the current study, we demonstrate deregulation of p53 controlled and mitochondria associated cell death processes. The study also reveals that treatment of TSC mutant cells with the drug candidate Proxison combined with reduced concentration of rapamycin can increase production of reactive oxygen species (ROS), can modify miRNA expression pattern associated with p53 regulation and can reduce cell viability. The online version contains supplementary material available at 10.1007/s10495-021-01670-4.
DOI: 10.1016/j.molmed.2010.09.002
发表时间: 2010-11
影响因子: 13.6
作者:
Dai C;Gu W
通讯作者: Gu W
DOI: 10.3390/biom8020014
发表时间: 2018-03-21
期刊: Biomolecules
影响因子: 5.5
作者:
Mrakovcic M;Fröhlich LF
通讯作者: Fröhlich LF
DOI: 10.4161/cc.22912
发表时间: 2013-01-01
期刊: CELL CYCLE
影响因子: 4.3
作者:
Hasty, Paul;Sharp, Zelton Dave;Campisi, Judith
通讯作者: Campisi, Judith
DOI: 10.1038/s41388-018-0625-1
发表时间: 2019-04-18
期刊: ONCOGENE
影响因子: 8
作者:
Abdelwahab, E. M. M.;Pal, S.;Pongracz, J. E.
通讯作者: Pongracz, J. E.
DOI: 10.1002/mc.20628
发表时间: 2010-06-01
影响因子: 4.6
作者:
Chen, Xian-Guo;Liu, Fei;Zhuang, Qian-Yuan
通讯作者: Zhuang, Qian-Yuan